https://www.selleckchem.com/TGF-beta.html
AEs of G2/3 dermatologic reaction (DR) of injection site had been identified in 15.6% and no other severe AEs were detected. Response rate in OC and CC were 22.9% and 20%, respectively. Median overall survival showed longer in performance status (PS) 0 (versus PS1/2), in CRP negative (versus positive) and in DR positive (versus negative) such as 8.7 m versus 1.2 m (p less then .001), 8.8 m versus 3.0 m (p less then .05) and 10.2 m versus 1.2 m (p less then .001), respectively. In conclusion, our vaccination therapy was feasible and effective in
Like
Comment
Share
